Subsequent immunochemistry staining confirmed that expression of GLS2, but not GLS1, was markedly elevated in MYCN-amplified tumors (samples 27, 9638 and 35313) when compared with the low-stage, non-amplified tumor (sample 20641, Figure 7C). This evidence concerns the gene MYCN and neoplasm.